Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder

Psychopharmacology (Berl). 2005 Aug;181(1):126-33. doi: 10.1007/s00213-005-2198-2. Epub 2005 Oct 15.

Abstract

Rationale: The depressive phase of bipolar disorder (bipolar depression) is a difficult-to-treat form of depression. The olanzapine/fluoxetine combination (Symbyax) is the only medication approved to treat this disorder. The precise neural mechanisms responsible for its efficacy are not clearly understood.

Objectives: In order to further elucidate the neurobiological mechanisms responsible for the beneficial clinical effects of the olanzapine/fluoxetine combination, the current experiment was designed to investigate the effects of chronic coadministration of olanzapine and fluoxetine on electrophysiological activity in the locus coeruleus (LC).

Methods: Rats received olanzapine for 3 weeks via subcutaneous osmotic pumps while simultaneously receiving daily intraperitoneal injections of fluoxetine. These chronically treated rats were anesthetized, and single-unit recordings of LC neurons were made.

Results: Chronic administration of olanzapine alone significantly increased firing of LC neurons, while, as reported previously, chronic administration of fluoxetine alone significantly reduced firing of LC neurons. However, in the combination condition, olanzapine was able to block the fluoxetine-induced suppression of the LC, and a significant increase in LC activity was observed.

Conclusions: The observed increase in firing of LC neurons could lead to enhanced levels of norepinephrine release in projection areas and amelioration of the clinical symptoms of bipolar depression.

Publication types

  • Comparative Study

MeSH terms

  • Action Potentials / drug effects
  • Animals
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / pharmacokinetics
  • Antipsychotic Agents / pharmacology
  • Benzodiazepines / blood
  • Benzodiazepines / pharmacokinetics
  • Benzodiazepines / pharmacology
  • Bipolar Disorder / etiology
  • Bipolar Disorder / physiopathology
  • Bipolar Disorder / prevention & control
  • Brain / metabolism
  • Drug Synergism
  • Fluoxetine / blood
  • Fluoxetine / pharmacokinetics
  • Fluoxetine / pharmacology*
  • Infusion Pumps
  • Injections, Intraperitoneal
  • Injections, Subcutaneous
  • Locus Coeruleus / cytology
  • Locus Coeruleus / drug effects*
  • Locus Coeruleus / physiology
  • Male
  • Neurons / cytology
  • Neurons / drug effects
  • Neurons / physiology
  • Olanzapine
  • Rats
  • Rats, Sprague-Dawley
  • Selective Serotonin Reuptake Inhibitors / administration & dosage
  • Selective Serotonin Reuptake Inhibitors / pharmacokinetics
  • Selective Serotonin Reuptake Inhibitors / pharmacology

Substances

  • Antipsychotic Agents
  • Serotonin Uptake Inhibitors
  • Fluoxetine
  • Benzodiazepines
  • Olanzapine